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Summary of the article's main point 
Transcriptional biomarkers are identified in peripheral blood discriminating active TB from latent TB infection and 
uninfected controls in HIV-infected individuals. These biomarkers can also be used to monitor TB treatment responses 
in HIV-infected individuals independent of HAART (in)eligibility and therapy. 
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Abstract 
Background: Limitations in diagnostic tools to discriminate between active and latent tuberculosis (TB) and for 
monitoring TB treatment responses are major challenges in TB control, especially in HIV-coinfected individuals. 
Methods: Expression levels of 105 immune-related genes were determined in 131 HIV patients with either active TB 
(48 HIV+TB+), latent TB (37 HIV+TST+) or no TB infection (46 HIV+TST-) in Addis Ababa, Ethiopia, using focused gene 
expression profiling by dual-color Reverse-Transcription Multiplex Ligation-dependent Probe Amplification assay. 
Results: Within the cohort of HIV+ subjects, the expression profiles of 7 genes at baseline (FCGR1A, RAB24, TLR1, 
TLR4, MMP9, NLRC4 and IL1B) could accurately discriminate between active TB disease versus both latently infected 
(LTBI) and uninfected controls, largely independently of (in)eligibility for highly active antiretroviral therapy (HAART). 
Following 6 months anti-TB treatment (ATT), biomarker profiles of TB patients became indistinguishable from those 
of LTBIs and uninfected controls. Importantly, host gene expression kinetics during TB treatment in HIV-coinfected 
individuals was found to be independent of HAART therapy. 
Conclusions: Blood transcriptomic profiles can potentially be used as biomarkers to discriminate the different clinical 
stages of TB in HIV-coinfected individuals and also be used to monitor TB treatment responses in both HAART treated 
and untreated individuals. 
 
 
Keywords: Tuberculosis, HIV, HAART, Treatment response biomarkers, Gene expression profiling. 
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Introduction 
Despite being a curable disease, tuberculosis (TB) has remained a major global health threat for centuries [1]. 
According to the World Health Organization, an estimated 10.4 million new TB cases and 1.8 million deaths, including 
0.4 million HIV-coinfected people, occurred in 2015 [2]. In addition, 1/4 of the worldwide population is latently 
infected with Mycobacterium tuberculosis (Mtb), an intracellular pathogen capable of infecting and surviving within 
the host’s mononuclear cells, particularly macrophages. Most immunocompetent individuals maintain a latent 
infection with only 5-10% lifelong risk of developing clinical disease [3]: the risk rises to 10% per year in HIV-
coinfected individuals due to lack of effective immunity, and extra-pulmonary disease is more likely [4]. 
The incidence of multi-drug resistant (MDR)-TB is increasing, in part due to non-adherence to lengthy 
treatment regimens. HIV coinfection has been associated with, and may contribute to, the increase in MDR-TB [5, 6]. 
Monitoring early treatment response is essential for effective administration of anti-TB treatment to prevent drug 
resistance. Currently used diagnostic methods to confirm active TB disease and monitor TB treatment responses, such 
as sputum smear microscopy and mycobacterial culture, have low sensitivity for predicting treatment failure and 
relapse during TB treatment [7], especially in HIV-coinfected individuals [8] due to low cavity formation. Another 
disadvantage of mycobacterial culture is the several weeks delay before results become available and subsequent 
therapy adjustment. Existing immunological methods to diagnose TB infection, such as the tuberculin skin test (TST) 
and Interferon-γ release assays, cannot distinguish between latent TB infection (LTBI) and active TB disease, and have 
poor sensitivity in children and immune-compromised individuals including HIV-coinfected TB patients [9]. Therefore, 
identification of biomarkers which classify clinical stages of TB and monitor TB treatment responses in HIV-coinfected 
individuals is essential for improving clinical practice. 
The interaction between the host immune response and Mtb has major roles in determining (i) clinical 
outcome following infection with Mtb and (ii) whether TB drug treatment will result in cure or treatment failure. 
Changes in gene expression patterns in blood resulting from the elicited immune responses could potentially be used 
as biomarkers to classify the different clinical outcomes of exposure to Mtb [10], including active disease or latent 
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infection, and for monitoring TB treatment responses [11-13]. However, most studies have been conducted in HIV-
uninfected subjects with only very few studies showing that blood gene expression profiles can distinguish active TB 
from LTBI in HIV-coinfected individuals [14, 15]. Importantly, the combined effect of TB treatment and highly active 
anti-retroviral therapy (HAART) on host gene expression in TB-HIV-coinfected individuals has never been studied. 
Therefore, in this study we aimed to identify candidate host gene biomarkers that classify active TB disease in HIV-
coinfected individuals, and that can be used to monitor TB treatment responses in TB-HIV patients, including those 
taking HAART, using focused gene expression profiling by dual-color Reverse-Transcription Multiplex Ligation-
dependent Probe Amplification (dcRT-MLPA). 
 
 
Materials and Methods 
Ethics statement 
All study participants provided written, informed consent at enrollment. Ethical clearance was obtained from the 
Scientific and Ethics Research Office (Ref:EHNRI 6.13/01), the Ethiopian Public Health Research Institute, and the 
London School of Hygiene & Tropical Medicine Ethics Review Committee (Ref:7174). 
 
Study design and population 
A longitudinal cohort study was conducted at St. Peter Specialized TB Hospital, Akaki and Kality Health Centers, Addis 
Ababa, Ethiopia between April 2007 and January 2011. A total of 131 adults of both sexes ranging between 15-65 
years old were enrolled. Participants were subdivided into three clinical study groups at enrollment and followed up 
at 6 (M6) and 18 (M18) months: 1) HIV-infected active TB patients (HIV+TB+, n=48) of whom 18 were on ATT and 13 
were on ATT-plus-HAART at M6; 2) HIV-infected TST positive subjects (HIV+TST+, n=37) of whom 20 were on HAART 
and 14 were naïve for HAART at M6; 3) HIV-infected TST negative subjects (HIV+TST-, n=46) of whom 26 were on 
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HAART and 16 were naïve for HAART at M6 (Supplementary Figure 1). Patients receiving HAART for <3 months or 
were lost during follow-up at M6 were excluded from the analysis. 
At recruitment, study participants were interviewed using a standard questionnaire and demographic data 
were collected. Exclusion criteria for enrollment were: refusal of HIV testing, pregnancy, co-morbidity with diabetes 
mellitus or chronic bronchitis, receiving steroid therapy, receiving TB and/or HAART treatment (at recruitment or 
previously), and alcohol or drug abuse that could compromise reliability. The initiation of HAART treatment at 
baseline or during follow-up visits was determined by the physician at the health center using the ART treatment 
national guidelines [16] including immunological criteria (CD4 count<200 cells/µl). HAART was provided free of charge 
to eligible patients. All active TB cases confirmed at enrollment were treated according to the national guideline [17]. 
 
Diagnostic assessment 
The HIV status was determined using the Determine HIV-½ (Abbott laboratories, Japan) screening test, the 
Capilus HIV-½ (TrinityBiotec, Ireland) confirmatory test and Unigold HIV-½ recombinant (TrinityBiotec, Ireland) as a tie 
breaker test [17]. The CD4 count was determined by flow cytometry using a FACS Calibur (Becton Dickinson, USA) 
while plasma HIV RNA viral load was determined using the NucliSensEasyQ NASBA diagnostic kit (OrganonTeknica, 
The Netherlands: detection range 50-3,000,000 copies/ml). 
Active TB diagnosis was based on both clinical and bacteriological parameters. At least two sputum smears 
(“spot-early morning”) were required to be positive by microscopy for Acid Fast Bacilli (AFB) using the Ziehl-Neelsen 
staining method (independent of the presence/absence of clinical parameters). There were no patients with dry 
cough in this study [17]. LTBI was determined by TST at baseline and follow-up visits for all participants except active 
TB patients according to the national guidelines [17]. 0.1ml tuberculin solution (RT23, State Serum Institute, 
Copenhagen) was injected intradermally into the dorsal surface of the forearm: TST-positivity was classified as skin 
induration diameter ≥5mm in HIV-infected individuals [17]. 
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RNA Extraction 
2.5ml venous blood was collected into PAXgene Blood RNA tubes (PreAnalytiX, Qiagen, Germany). RNA was 
extracted using the PAXgene Blood RNA extraction kit (PreAnalytiX, Qiagen) according to the manufacturer’s 
instructions. Briefly, PAXgene tubes were centrifuged at 1800g/10 minutes, pellets were lysed, resuspended, and 
treated with proteinase K to remove contaminating proteins. Ethanol-precipitated nucleic acids were loaded onto 
spin columns, and DNA was digested using on-column RNase-free DNase (Qiagen). Purified RNA was eluted with 
RNase-free buffer (BR5 buffer) and quantified using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, 
Wilmington, USA). RNA samples with absorbance 260/280nm ratios <1.70 or >2.3 were excluded from further 
analyses. 
 
Dual-color Reverse-Transcription Multiplex Ligation-dependent Probe Amplification (dcRT-MLPA) 
DcRT-MLPA was performed as previously described [12]. Briefly, for each target‐specific sequence, a specific 
RT primer was designed located immediately downstream of the left and right hand half‐probe target sequence. RNA 
was reverse transcribed using RT-primer mix and MMLV reverse transcriptase (Promega, USA). Transcriptase activity 
was inactivated by heating at 98oC/2 minutes. Following reverse transcription, left and right hand half‐probes were 
hybridized to the cDNA at 60°C overnight. Annealed half‐probes were ligated using ligase 65 and subsequently 
amplified by PCR (33 cycles of 30s/95°C, 30s/58°C, 60s/72°C, followed by 1 cycle of 20 min/72°C). Primers and probes 
were from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands) and MLPA reagents from MRC-Holland (Amsterdam, 
The Netherlands). PCR amplification products were 1:10 diluted in HiDi-formamide containing 400HD ROX size 
standard, denatured at 95oC/5 min, ice-cooled and analyzed on an Applied Biosystems 3730 capillary sequencer in 
GeneScan mode (BaseClear, Leiden, The Netherlands). 
Trace data were analyzed using GeneMapper software 5 (Applied Biosystems). The areas of each assigned 
peak (arbitrary units) were exported for analysis in Microsoft Excel. Data were normalized to GAPDH and signals 
below the threshold value for noise cutoff in GeneMapper (log2 transformed peak area 7.64) were assigned the 
threshold value for noise cutoff. Finally, the normalized data were log2 transformed for statistical analysis. 
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RT primers and half-probes were designed by Leiden University Medical Centre (LUMC, Leiden, The 
Netherlands) [12, 18] and comprised sequences for 4 housekeeping genes and 105 selected genes to profile the 
innate and adaptive immune responses (Supplementary Table 1). 
 
Statistical analysis 
A non-parametric Kruskal-Wallis test was performed to compare data between more than two clinical groups, 
while a two-tailed Wilcoxon rank-sum (Mann-Whitney) test for unpaired data or a Wilcoxon signed-rank test for 
paired data was performed to compare data between two clinical groups. A Chi2 test was used to compare the 
different proportions of dichotomous variables amongst the groups. All data analysis was done using Inter cooled 
STATA version 11.0 (College Station, Texas, USA). The statistical significance cut-off level was p<0.05. 
 
 
Results 
Characteristics of the study population at baseline. 
Altogether, 131 study participants categorized into 48 HIV+TB+ (active TB cases), 37 HIV+TST+ (LTBI 
individuals) and 46 HIV+TST- (TB uninfected controls), were included. Baseline demographic, clinical and laboratory 
data of each study group is shown in Supplementary Tables 2A and 2B. The mean age (±S.D.) of HIV+TB+, HIV+TST+ 
and HIV+TST- subjects was 32.6±7.8, 34.2±8.02 and 32.8±6.8 respectively while 50% of HIV+TB+, 61% of HIV+TST+ and 
72% of HIV+TST- subjects were female. 
Statistically significant differences between groups were observed in the proportion of patients with 
malnutrition (Body Mass Index (BMI) <18.50 kg/m2) [19] and HIV-1 viral load (Supplementary Table 2A). HIV+TB+ 
patients presented with lower BMI (p=0.0001 and 0.0013), lower CD4+ T-cell counts (p=0.0335 and 0.0185), and 
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higher HIV RNA levels (p=0.028 and 0.046) than HIV+TST+ and HIV+TST- subjects, respectively, whereas no significant 
differences in these parameters were observed between HIV+TST+ and HIV+TST- individuals. 
 
Gene expression profiles of clinical stages of TB in HIV-infected individuals. 
Whole blood gene expression profiles of 48 HIV+TB+, 37 HIV+TST+ and 46 HIV+TST- individuals were analyzed 
by dcRT-MLPA using probe sets for 105 selected genes to profile innate and adaptive immune responses 
(Supplementary Table 1). 36 out of 105 genes examined were differentially expressed between the three clinical 
groups and 26 of these genes discriminated between active disease (HIV+TB+) and latent infection (HIV+TST+) in HIV-
coinfected individuals (Table 1). 21 genes were significantly more highly expressed during active disease than latent 
infection (PTPRCv2, IL1B, IL15, IL42, IL9, IL22RA1, TGFB1, FLCN1, TNFRSF1A, FPR1, CLEC7A, NLRC4, NLRP12, MMP9, 
LTF, TLR1, TLR2, TLR4, TLR8, FCGR1A and RAB24), while five genes (CD4, PTPRCv1, TLR3, BLR1 and ZNF331) exhibited 
significantly lower expression in HIV+TB+ than HIV+TST+ subjects. The lower levels of CD4 transcripts in HIV+TB+ 
patients compared to HIV+TST+ (and also HIV+TST-) individuals is consistent with the lower CD4+ T-cell counts 
observed in active TB cases (Supplementary Table 2A). 
With the exception of TGFB1, all other 35 genes were differentially expressed between HIV-infected TB cases 
and HIV-infected TST- controls. 24 genes had significantly higher expression in HIV+TB+ than HIV+TST- controls (IL15, 
IL22RA1, FPR1, PTPRCv2, IL1B, IL42, IL9, FLCN1, TNFRSF1A, CLEC7A, NLRC4, NLRP12, MMP9, LTF, TLR1, TLR2, TLR4, 
TLR8, FCGR1A, RAB24, TLR6, CCL19, SPP1 and TIMP2), whereas 11 genes had significantly lower expression in TB cases 
compared to uninfected controls (CD3E, CD4, IL7R, PTPRCv1, TBX21, GZMB, GNLY, CCL5, TLR3, BLR1 and ZNF331). 25 
of the 35 genes that were differentially expressed between active TB cases and uninfected controls also discriminated 
between active TB cases and LTBIs (PTPRCv2, IL1B, IL15, IL42, IL9, IL22RA1, FLCN1, TNFRSF1A, FPR1, CLEC7A, NLRC4, 
NLRP12, MMP9, LTF, TLR1, TLR2, TLR4, TLR8, FCGR1A, RAB24, CD4, PTPRCv1, TLR3, BLR1 and ZNF331) (Table 1), 
suggesting that these biomarkers are strongly associated with TB disease in HIV-coinfected individuals. 
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As expected, only a limited number of genes distinguished between LTBIs and TST- controls in HIV-infected 
individuals (Table 1), in line with our previous studies in HIV-uninfected individuals [12]. From the 10 genes that were 
differentially expressed, 4 genes (IL15, FPR1, TLR6 and SPP1) had significantly higher expression in HIV+TST+ 
compared to HIV+TST- individuals, whereas 6 genes (CD3E, IL7R, TGFB1, GNLY, GZMB and CCL5) had significantly 
lower expression. 
Non-parametric Receiver Operator Characteristic (ROC) curves to determine the discriminatory potential of 
single genes identified TGFB1, FCGR1A, RAB24, PTPRCv2, TLR1, TLR4, MMP9, NLRC4 and IL1B, with Area Under the 
Curve (AUCs) of 1.00, 0.81, 0.79, 0.79, 0.77, 0.76, 0.75, 0.75 and 0.75 respectively, as genes with the most powerful 
classifying potential to discriminate between active TB disease and latent TB infection in HIV-coinfected individuals 
(Figure 1A). The expression profiles of these signature genes are displayed in Figure 2. Genes that could best classify 
HIV+TB+ and HIV+TST- were FCGR1A, NLRC4, TLR1, RAB24, TLR4, TLR2, MMP9, FPR1 and IL1B, with AUCs of 0.90, 
0.82, 0.81, 0.80, 0.80, 0.78, 0.76, 0.75 and 0.75 respectively (Figure 1B). Transcriptomic profiles of genes that 
markedly classified HIV+TB+ and HIV+TST- individuals are displayed in Figure 2. Seven of nine single genes that could 
discriminate between active TB cases and uninfected controls also discriminated between active TB cases and LTBIs, 
again suggesting these coinciding biomarkers are strongly associated with TB disease in HIV-coinfected individuals. 
Genes that were differentially expressed between LTBIs and TST- controls in HIV-infected individuals had limited 
classifying value (AUCs of <0.70), as expected. 
 
Transcriptomic profiles of anti-TB treatment (ATT) responses in HIV-coinfected TB patients are independent of 
HAART therapy. 
To determine if (in)eligibility for HAART might be a confounding parameter in the analysis of TB treatment 
responses, study groups (HIV+TB+, HIV+TST+, HIV+TST-) were stratified at baseline as either eligible or ineligible for 
HAART, and gene expression profiles were compared (Table 2A). Clearly, very few genes were found to be 
differentially expressed within each study group when individuals were stratified based on in(eligibility) for HAART. 
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From the 36 genes that were differentially expressed among the study groups before stratification, only 1 gene 
(IL4δ2) was differentially expressed between HAART-eligible and -ineligible HIV+TB+, 5 genes (TNFRSF1A, TLR4, 
NLRC4, LTF and BLR1) were differentially expressed between HAART-eligible and -ineligible HIV+TST+ and 3 genes 
(IL7R, GZMB and TLR6) were differentially expressed between HAART-eligible and -ineligible HIV+TST-. Together, 
these data indicate that stratification based on in(eligibility) for HAART is not a dominant confounding factor in the 
analysis of TB treatment responses. 
Similarly, following 6 months of ATT and/or HAART therapy, only a limited number of genes was found to be 
differentially expressed between ATT and ATT-plus-HAART treated HIV+TB+ patients, HAART treated and untreated 
HIV+TST+ subjects, and HAART treated and untreated HIV+TST- individuals (Table 2B). From the 36 genes that were 
found to be differentially expressed among the study groups before stratification based on HAART in(eligibility), only 
2 genes (TGFB1 and BLR1) were differentially expressed between ATT and ATT-plus-HAART treated HIV+TB+ patients, 
2 genes (GNLY and MMP9) were differentially expressed between HAART treated and untreated HIV+TST+ subjects 
and 4 genes (IL7R, CCL19, TLR6 and MMP9) were differentially expressed between HAART treated and untreated 
HIV+TST- individuals, suggesting that treatment with HAART merely affects the direct ex vivo RNA expression profile 
in peripheral blood of HIV-infected individuals. 
Importantly, while baseline biomarker profiles were identified in HIV-infected individuals that markedly 
discriminated between active TB cases versus LTBIs and uninfected controls (Table 1), longitudinal follow-up analysis 
showed that biomarker profil s of treated TB patients became indistinguishable from those of LTBIs and uninfected 
controls at the end of 6 months ATT therapy. This outcome was independent of HAART (in)eligibility and HAART 
treatment (Tables 3A and B and Supplementary Figure 2). In summary, these data show that transcriptomic profiles of 
ATT treatment responses in HIV-coinfected TB patients are independent of HAART therapy and normalize to levels 
observed in latently TB-infected and uninfected controls after completion of ATT. 
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Discussion 
Identification of biomarkers that can discriminate between active and latent TB is essential for controlling the 
spread of TB worldwide, especially in HIV-infected subjects. Furthermore, biomarkers that can monitor TB treatment 
responses and evaluate ATT efficacy could potentially reduce de novo drug resistance development [20]. Here, we 
used a focused gene expression profiling platform, dcRT-MLPA [12], targeting innate and adaptive immune response 
genes, to analyze RNA expression levels of 105 pre-selected genes in peripheral blood of HIV-infected individuals and 
identified biomarkers with excellent discriminatory capacity. At baseline, expression levels of 7 single genes (FCGR1A, 
RAB24, TLR1, TLR4, MMP9, NLRC4 and IL1B) could accurately discriminate between active TB versus both LTBIs and 
uninfected controls with AUCs ≥75, indicating these interrelating biomarkers are strongly associated with TB disease 
in HIV-coinfected individuals. In contrast, all genes that were differentially expressed between LTBIs and uninfected 
controls had limited classifying value (AUC<70), in accordance with previous studies in HIV-uninfected populations 
[12]. 
The observed higher expression of immune-related genes in HIV-infected individuals with active TB may be 
due to an increased load of bacterial antigens from actively replicating bacilli, triggering a vigorous host immune 
response. In contrast, lower expression of T-cell associated genes (e.g. CD4 and PTPRCv1) in these TB patients may 
reflect HIV-related cell depletion and/or cell migration to the lungs as the primary infection site. This peripheral T-cell 
depletion may be one underlying mechanism by which TB disease aggravates HIV-infection progression [21]. 
TGFB1 expression was significantly higher in HIV-infected participants with active TB disease compared to 
latent TB infection, in contrast to previous reports in HIV-uninfected participants in South Africa and Malawi [15]. 
TGFB1 is involved in the induction of fibrosis, a hallmark presentation of tuberculosis disease, and excessive TGFB1 
during tuberculosis may enhance viral activity, thereby accelerating HIV disease [22]. Concentrations of TGFB1 
cytokine were about twofold higher in PPD-induced culture supernatants of HIV-infected patients with tuberculosis 
[23]. Therefore, elevation of TGFB1 gene expression levels in TB-HIV patients may result in enhanced T-cell 
suppression and HIV as well as TB propagation. 
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Within our HIV-infected cohort, FCGR1A was amongst the strongest differentially expressed genes, with 
marked discriminatory power between active TB cases versus both LTBIs and uninfected controls. This is consistent 
with gene expression profiles of PBMCs and whole blood from TB patients and healthy donors in HIV-uninfected 
populations of different ethnic backgrounds [24-26]. Moreover, Sutherland et.al. recently reported transcript levels of 
FCGR1A as the most reliable classifier of active TB compared to latent TB and Mtb-uninfected controls regardless of 
HIV status and genetic background [15]. FCGR1A is an essential component of interferon signaling and plays a central 
role in endocytosis, phagocytosis, antibody-dependent cellular toxicity, cytokine release, and superoxide generation 
[27] but may participate in TB pathogenesis. 
Transcript levels of TLR1, TLR2, TLR4, RAB24 and MMP9 were also higher in HIV+TB+ patients compared to 
HIV+TST+ and HIV+TST- subjects, in agreement with published data in HIV-uninfected subjects [28, 29], suggesting a 
biomarker signature encompassing these genes and also including FCGR1A may be useful in classifying different 
clinical stages of TB both in HIV-uninfected and HIV-infected individuals. Although these genes display comparable 
expression patterns between study groups and similar expression kinetics during ATT therapy, their functional roles 
during TB infection is diverse. RAB24 is involved in intracellular trafficking [30] and the increase in RAB24 expression 
in TB-infected monocytes has been correlated to increased autophagic activity [29]. Pattern recognition receptors are 
the first line of recognition of Mtb bacilli and have a critical role in initiating innate and subsequent adaptive immune 
responses. TLR1 and TLR2 play an important role in host defense against mycobacteria, especially by mediating 
responses to mycobacterial triacylated lipopeptides [31]. In addition, the ability of Mtb to inhibit major 
histocompatibility complex Class II expression and antigen presentation through stimulation of TLR2 and TLR1 creates 
a niche for survival of Mtb in macrophages and promotes its evasion of recognition by CD4+ T-cells [28]. Finally, 
higher expression levels of MMP9 have been shown to correlate with dysregulation of cellular apoptosis in HIV-TB-
coinfected patients [32] and with early dissemination of Mtb followed by recruitment of macrophages, induction of 
Th1-type immunity and granuloma formation [33]. 
The LTBI patients recruited into this study likely reflect a heterogeneous group of individuals, including some 
with quiescent Mtb infection and others with asymptomatic subclinical disease [34]: future work could test whether 
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the gene expression signatures are able to discriminate these subgroups. Additionally, the current study only included 
microbiologically confirmed active TB cases: future work could determine the utility of the gene expression in a wider 
range of clinically suspected TB. 
Most genes that were differentially expressed at baseline, between HIV-infected subjects with active TB 
versus those with latent TB infection or uninfected controls, normalized during ATT treatment of (HAART-treated) TB 
patients to levels observed in (HAART-treated) LTBIs and uninfected control subjects. Normalization of gene 
expression profiles in TB patients during 6 months anti-TB chemotherapy has previously been reported in HIV-
uninfected TB patients [10, 35, 36] and correlates with clinical cure [11]. 
Interestingly, only a few genes were differentially expressed at baseline between study groups eligible and 
ineligible for HAART, excluding (in)eligibility for HAART as a confounding factor when analyzing the kinetic response of 
TB treatment at the transcriptomic level. Moreover, HAART therapy of eligible HIV+TB+, HIV+TST+, and HIV+TST- 
subjects only marginally affected transcriptomic profiles. This suggests that a similar biomarker signature can be used 
to monitor ATT treatment efficacy in TB-HIV patients both eligible and ineligible for HAART. 
In conclusion, the expression of several single genes (FCGR1A, RAB24, TLR1, TLR4, MMP9, NLRC4 and IL1B) in 
peripheral blood can discriminate active TB from latent TB infection and uninfected controls in HIV-infected 
individuals. These biomarkers can also be used to monitor TB treatment responses in HIV-infected individuals 
independent of HAART (in)eligibility and therapy. Potentially, in the future, the identified biomarkers could be applied 
to facilitate evaluation of new tuberculosis chemotherapeutic regimens and for vaccines trials, regardless of HAART. 
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Figure legends 
Figure 1. Identification of single genes with discriminatory power to classify study groups. 
Receiver operator characteristics (ROC) curves showing the accuracies of individual genes in discriminating 
(A) HIV+TB+ versus HIV+TST+ subjects and (B) HIV+TB+ versus HIV+TST- subjects. AUC = Area under the curve. 
 
Figure 2. Gene expression profiles of signature genes. 
Median gene expression levels (peak areas normalized to GAPDH and log2-transformed) of the indicated genes are 
shown as box-and-whisker plots (5-95 percentiles). Significant differences among the groups and between study 
groups were determined using Kruskal-Wallis H test and Wilcoxon Mann-Whitney test respectively. Shown are 
individual genes that were found to have the best discriminatory power to distinguish between active TB cases 
(HIV+TB+) versus latently infected (HIV+TST+) and uninfected (HIV+TST-) controls. (* = P-value ≤0.05, ** = P-value 
≤0.01, *** = P-value ≤0.001, **** = P-value ≤0.0001). 
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Table 1. Gene expression profiles differentiating between study groups at baseline (Month 0). 
 
Gene Symbol HIV+TB+ 
(n=47) 
HIV+TST+ (n=37) HIV+TST- 
(n=46) 
HIV+TB+ 
vs  HIV+TST+ 
P-value 
HIV+TB+ 
vs  HIV+TST- 
P-value 
HIV+TST+ 
vs  HIV+TST- 
P-value 
T cell subset markers      
CD3E 13.0 (11.8-13.5) 13.2 (12.1-13.6) 13.6 (12.6-13.9) 0.2324 0.0015 0.0232 
CD4 11.4 (10.5-12.1) 11.8 (11.2-12.6) 12.1 (11.6-12.5) 0.0025 0.0002 0.8940 
IL7R 11.7 (10.6-12.2) 12.0 (11.1-12.7) 12.3 (11.7-13.3) 0.2137 0.0017 0.0373 
PTPRCv1 10.5 (9.8-11.3) 11.0 (10.5-11.5) 11.4 (10.9-11.9) 0.0285 0.0005 0.1213 
PTPRCv2 13.3 (12.8-13.6) 12.4 (11.9-12.9) 12.8 (12.2-13.0) 0.0000 0.0002 0.2776 
Th1/2/9/17 associated genes/Treg associated genes     
IL1B 11.4 (10.9-11.8) 10.5 (9.9-11.4) 10.5 (9.7-11.1) 0.0002 0.0000 0.6785 
IL15 7.9 (7.6-8.3) 7.6 (7.6-8.0) 7.6 (7.6-7.6) 0.0326 0.0000 0.0290 
TBX21 7.6 (7.6-7.6) 7.6 (7.6-7.6) 7.6 (7.6-8.1) 0.0971 0.0011 0.0976 
IL4δ2 7.6 (7.6-11.2) 7.6 (7.6-7.6) 7.6 (7.6-7.6) 0.0136 0.0004 0.2313 
IL9 9.9 (9.5-10.4) 9.5 (8.6-10.0) 9.5 (8.9-9.9) 0.0041 0.0004 0.8087 
IL22RA1 7.7 (7.6-8.5) 7.6 (7.6-7.6) 7.6 (7.6-7.6) 0.0027 0.0002 0.6352 
TGFB1 14.4 (14.2-14.6) 11.6 (11.1-12.1) 14.3 (14.1-14.5) 0.0000 0.4134 0.0000 
Cytotoxicity genes      
GNLY 13.9 (12.6-14.3) 13.7 (13.1-14.3) 14.5 (13.4-15.2) 0.9685 0.0032 0.0023 
GZMB 12.7 (12.2-13.0) 12.6 (11.8-13.0) 13.1 (12.3-13.7) 0.7003 0.0208 0.0097 
Apoptosis/survival      
FLCN1 7.7 (7.6-8.3) 7.6 (7.6-7.6) 7.6 (7.6-7.8) 0.0037 0.0306 0.3708 
TNFRSF1A 13.3 (13.1-13.8) 12.7 (12.0-13.4) 12.8 (12.2-13.3) 0.0024 0.0002 0.9253 
Myeloid associated genes      
CCL5 14.6 (14.0-14.9) 14.7 (14.3-14.9) 15.0 (14.4-15.3) 0.2865 0.0050 0.0330 
FPR1 13.9 (13.3-14.4)  13.4 (12.6-14.0) 12.7 (12.2-13.7) 0.0220 0.0001 0.0401 
Chemokines      
CCL19 8.8 (8.0-9.2) 8.6 (8.2-9.0) 8.1 (7.6-8.8) 0.3645 0.0158 0.0992 
Pattern recognition receptors      
CLEC7A 12.9 (12.3-13.4) 12.4 (11.7-12.9) 12.2 (11.6-12.7) 0.0041 0.0001 0.4127 
TLR1 12.0 (11.3-12.3) 11.1 (9.9-11.6) 10.9 (10.0-11.3) 0.0000 0.0000 0.4592 
TLR2 10.0 (9.3-10.6) 9.0 (8.0-10.0) 9.0 (8.4-9.3) 0.0005 0.0000 0.7898 
TLR3 10.3 (9.7-10.8) 10.9 (10.0-11.3) 11.0 (9.9-11.4) 0.0199 0.0212 0.6497 
TLR4 10.6 (10.0-11.0) 9.8 (9.0-10.4) 9.6 (8.9-10.2) 0.0001 0.0000 0.5439 
TLR6 10.1 (9.6-10.4) 9.8 (9.5-10.2) 9.6 (9.1-9.9) 0.1524 0.0012 0.0373 
TLR8 11.7 (10.4-12.3) 10.7 (8.5-11.5) 10.7 (10.0-11.1) 0.0017 0.0011 0.7779 
Inflammasome components      
NLRC4 9.8 (9.5-10.2) 9.2 (8.8- 9.5) 9.0 (8.8-9.4) 0.0001 0.0000 0.3587 
NLRP12 8.2 (7.9-8.6) 7.8 (7.6-8.3) 7.9 (7.6-8.4) 0.0158 0.0248 0.8823 
IFN signalling genes      
FCGR1A 11.4 (10.8-11.8) 9.9 (8.5-10.8) 9.2 (8.7-9.8) 0.0000 0.0000 0.0554 
Inflammation      
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Median (inter quartile range) gene expression values (peak areas normalized for GAPDH and log2-transformed) are 
shown at baseline and significant differences between study groups were determined using Kruskal-Wallis H and 
Wilcoxon Mann-Whitney test. In pink: genes are indicated that were more highly expressed in the test group 
compared to the reference/control group. In blue: genes are indicated that had lower expression in the test group 
compared to the reference/control group. Only genes whose expression level significantly differed between any of 
the study groups are listed. 
 
MMP9 10.5 (9.2-11.3) 9.2 (7.6-9.8) 8.3 (7.6-9.7) 0.0001 0.0000 0.6271 
SPP1 7.6 (7.6-8.1) 7.6 (7.6-7.8) 7.6 (7.6-7.6) 0.4728 0.0038 0.0442 
TIMP2 14.2 (13.5-15.0) 14.1 (13.3-14.5) 13.5 (12.8-14.4) 0.1414 0.0045 0.2865 
Other       
RAB24 11.6 (11.2-12.0) 10.7 (9.9-11.3) 10.6 (9.9-11.1) 0.0000 0.0000 0.8051 
LTF 9.2 (8.3-10.4) 7.9 (7.6-9.0) 7.9 (7.6-9.5) 0.0015 0.0058 0.7537 
ZNF331 7.6 (7.6-8.7) 8.5 (7.6-9.5) 8.5 (7.6-9.3) 0.0185 0.0306 0.7857 
BLR1 9.5 (9.0-9.9) 10.0 (9.6-10.7) 10.2 (9.5-10.8) 0.0001 0.0002 0.9764 
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Table 2A. Baseline (Month 0) gene expression profiles after stratification by HAART (in)eligibility. 
Gene HIV+TB+ HIV+TB+ HIV+TB+ HAART- HIV+TST+ HIV+TST+ HIV+TST+ HAART- HIV+TST- HIV+TST- HIV+TST- HAART- 
Symbol HAART- HAART+ vs HAART- HAART+ vs HAART- HAART+ vs 
 (n=18) (n=13) HIV+TB+ HAART+ (n=14) (n=20) HIV+TST+ HAART+ (n=16) (n=26) HIV+TST- HAART+ 
 
  
P-value 
  
P-value 
  
P-value 
T cell subset markers 
      
 
CD3E 13.0 (12.5-13.4) 13.0 (12.3-13.7) 0.9833 
 
13.2 (12.1-13.6) 13.3 (12.4-13.7) 0.7021 13.8 (13.6-13.8) 13.2 (12.5-13.9) 0.3635 
CD4 11.5 (10.8-12.0) 11.7 (10.7-12.2) 0.5994 11.9 (11.0-13.0) 12.3 (11.5-12.5) 0.9419 12.2 (11.9-12.7) 12.1 (11.4-12.3) 0.3227 
IL7R 11.9 (10.9-12.2) 11.6 (10.8-12.3) 0.7220 12.1 (11.4-12.9) 11.8 (10.6-12.7) 0.4663 13.2 (12.2-13.5) 11.7 (10.8-12.5) 0.0006 
PTPRCv1 10.1 (9.8-11.5) 10.9 (10.5-11.4) 0.2330 11.0 (10.5-11.5) 11.0 (10.5-11.8) 0.6887 11.6 (11.1-12.2) 11.2 (10.8-11.7) 0.2042 
PTPRCv2 13.4 (13.0-13.7) 13.3 (12.9-13.4) 0.5165 12.1 (11.1-12.7) 12.5 (12.0-12.9) 0.1173 12.9 (12.7-13.2) 12.7 (11.8-13.1) 0.1606 
Th1/2/9/17 associated genes/Treg associated genes  
IL1B 11.6 (11.2-11.8) 11.3 (11.0-11.5) 0.2170 10.0 (9.6-11.3) 10.8 (10.2-11.5) 0.1663 10.5 (9.9-11.1) 10.2 (9.7-11.4) 0.6885 
 
IL15 7.8 (7.6-8.2) 7.9 (7.6-8.3) 0.6467 7.6 (7.6-7.8) 7.6 (7.6-8.1) 0.3317 7.6 (7.6-7.6) 7.6 (7.6-7.6) 0.8620 
TBX21 7.6 (7.6-7.6) 7.6 (7.6-7.6) 0.4452 7.6 (7.6-7.6) 7.6 (7.6-8.1) 0.4977 7.6 (7.6-7.8) 7.6 (7.6-8.2) 0.3015 
 
IL4δ2 10.5 (7.6-12.1) 7.6 (7.6-7.6) 0.0311 7.6 (7.6-7.6) 7.6 (7.6-7.6) 0.8585 
 
7.6 (7.6-7.6) 7.6 (7.6-7.6) 0.8824 
IL9 10.3 (9.6-10.5) 10.0 (9.7-10.2) 0.4388 9.5 (8.4-10.0) 9.6 (9.2-10.2) 0.3816 9.5 (8.7-9.7) 9.5 (9.1-10.2) 0.1378 
IL22RA1 7.8 (7.6-9.0) 7.6 (7.6-7.9) 0.2097 7.6 (7.9-7.6) 7.6 (7.6-7.6) 0.6260 7.6 (7.6-7.6) 7.6 (7.6-7.6) 0.5428 
TGFB1 14.4 (14.2-14.5) 14.5 (14.4-14.7) 0.2170 11.4 (9.2-12.0) 11.6 (11.4-12.1) 0.3721 
 
14.2 (14.1-14.6) 14.3 (14.0-14.5) 0.9787 
Cytotoxicity genes 
      
 
GNLY 14.0 (12.8-14.3) 13.9 (13.5-14.3) 0.4898 13.3 (13.0-14.1) 14.0 (13.7-14.4) 0.0492 14.5 (14.2-15.2) 14.4 (13.2-15.2) 0.4383 
GZMB 12.6 (12.1-13.0) 12.8 (12.6-13.0) 0.1738 12.7 (11.8-13.2) 12.7 (12.2-13.0) 0.8842 
 
12.6 (11.8-13.4) 13.4 (12.6-13.8) 0.0111 
 
Apoptosis/survival 
      
 
FLCN1 7.6 (7.6-8.2) 8.2 (7.8-8.5) 0.1003 7.6 (7.6-7.6) 7.6 (7.6-7.7) 0.5611 7.6 (7.6-8.0) 7.6 (7.6-7.7) 0.9098 
 
TNFRSF1A 13.4 (13.2-13.8) 13.4 (13.1-13.7) 0.8506 12.2 (11.9-12.9) 13.2 (12.5-13.4) 0.0414 12.8 (12.4-13.2) 12.7 (12.2-13.2) 0.4383 
Myeloid associated genes 
   
CCL5 14.6 (14.0-14.8) 14.8 (14.6-15.0) 0.1874 14.7 (13.9-14.9) 14.7 (14.5-15.0) 0.3625 14.8 (14.2-15.1) 15.0 (14.7-15.4) 0.1211 
 
FPR1 14.0 (13.2-14.4) 13.9 (13.6-14.4) 0.6909 12.7 (12.5-14.0) 13.4 (12.9-14.0) 0.2438 12.9 (12.4-13.5) 12.8 (12.2-13.8) 0.6885 
Chemokines 
      
CCL19 8.9 (8.4-9.2) 8.3 (7.6-8.9) 0.1242 8.6 (8.2-9.1) 8.6 (7.6-9.0) 0.4868 7.9 (7.6-8.7) 8.2 (7.6-9.0) 0.2875 
Pattern recognition receptors 
   
 
CLEC7A 13.1 (12.8-13.5) 12.9 (12.6-13.5) 0.4144 12.0 (10.6-13.0) 12.5 (12.1-12.9) 0.2293 12.1 (11.5-12.6) 12.3 (11.5-12.7) 0.7996 
TLR1 12.0 (11.6-12.6) 12.0 (11.5-12.3) 0.8835 10.6 (9.0-11.4) 11.2 (10.8-11.6) 0.1172 10.9 (10.3-11.4) 10.9 (9.8-11.2) 0.7182 
 
TLR2 10.1 (9.3-10.6) 9.9 (9.6-10.5) 0.6603 8.9 (7.6-9.4) 9.1 (8.3-10.2) 0.0935 8.8 (8.3-9.1) 9.1 (8.5-9.7) 0.1527 
TLR3 10.3 (10.2-10.7) 10.2 (9.8-10.7) 0.5721 10.9 (10.4-11.4) 10.9 (9.8-11.3) 0.8555 
 
11.0 (10.6-11.4) 10.8 (9.9-11.6) 0.5470 
TLR4 10.4 (10.2-11.0) 10.6 (10.2-11.0) 0.9833 9.4 (8.3-10.1) 10.1 (9.3-10.4) 0.0414 9.8 (9.1-10.2) 9.5 (8.8-10.2) 0.6689 
TLR6 9.9 (9.6-10.2) 10.1 (9.8-10.4) 0.7536 9.9 (9.5-10.3) 9.8 (9.5-10.2) 0.6620 9.8 (9.6-10.2) 9.4 (9.1-9.9) 0.0304 
TLR8 11.8 (10.7-12.4) 11.4 (10.0-12.2) 0.4898 10.6 (7.6-11.0) 11.0 (10.2-11.8) 0.0933 10.9 (10.2-11.2) 10.4 (8.4-10.8) 0.0726 
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Inflammasome components 
   
 
NLRC4 9.9 (9.6-10.2) 9.8 (9.6-10.0) 0.3909 9.0 (8.8-9.2) 9.4 (9.0-9.8) 0.0492 9.2 (8.9-9.4) 9.1 (8.8-9.4) 0.4074 
NLRP12 8.5 (8.0-8.7) 8.2 (8.0-8.6) 0.5860 7.7 (7.6-7.9) 8.1 (7.6-8.3) 0.0967 7.9 (7.6-8.4) 7.9 (7.6-8.3) 0.8341 
IFN signalling genes 
      
 
FCGR1A 11.4 (10.8-11.8) 11.4 (11.0-11.9) 0.5165 9.7 (7.7-10.4) 9.9 (9.3-11.2) 0.2292 
 
9.1 (8.2-9.4) 9.4 (8.9-10.4) 0.1521 
Inflammation 
      
 
MMP9 10.9 (8.7-11.4) 10.2 (9.1-10.5) 0.2566 7.6 (7.6-9.3) 9.3 (7.7-9.8) 0.0620 
 
8.9 (7.6-10.0) 8.0 (7.6-9.4) 0.4486 
SPP1 7.6 (7.6-8.2) 7.6 (7.6-7.6) 0.3308 
 
7.6 (7.6-7.9) 7.6 (7.6-7.8) 0.7103 7.6 (7.6-7.6) 7.6 (7.6-7.6) 1.0000 
 
TIMP2 14.2 (13.7-14.9) 14.5 (13.9-15.3) 0.5165 13.3 (13.0-14.5) 14.2 (13.4-14.5) 0.1260 13.4 (12.8-14.1) 13.5 (13.0-14.8) 0.3778 
Other 
        
RAB24 11.6 (10.8-12.0) 11.9 (11.5-12.0) 0.2170 10.2 (8.2-11.3) 10.7 (10.2-11.5) 0.1172 10.6 (10.3-11.0) 10.8 (9.9-11.2) 0.9148 
LTF 9.1 (8.4-10.7) 8.8 (7.6-9.7) 0.3445 7.6 (7.6-7.7) 8.2 (7.6-9.9) 0.0100 7.6 (7.6-10.4) 8.1 (7.6-9.7) 0.3749 
ZNF331 7.6 (7.6-9.1) 7.8 (7.6-8.0) 0.8737 
 
9.3 (7.6-10.3) 7.9 (7.6-9.2) 0.0860 8.2 (7.6-9.1) 8.7 (7.6-9.3) 0.7538 
BLR1 9.6 (9.3-9.9) 9.4 (9.1-10.1) 0.9499 10.3 (10.0-11.1) 9.8 (9.6-10.7) 0.0414 10.2 (9.7-10.8) 10.1 (9.5-10.6) 0.4871 
 
Median (inter quartile range) gene expression values (peak areas normalized for GAPDH and log2-transformed) are shown at baseline. Significant differences within each study group after 
stratification by HAART (in)eligibility were determined using Wilcoxon Mann-Whitney test. In pink: genes are indicated that were more highly expressed in the HAART eligible group compared 
to the HAART ineligible group. In blue: genes are indicated that had lower expression in the HAART eligible group compared to the HAART ineligible group. Genes listed in this table were 
differentially expressed between any of the study groups before stratification by HAART (in)eligibility (Table 1). 
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Table 2B. Effect of HAART on the ATT induced treatment response transcriptomic profiles (Month 6). 
Gene 
Symbol 
HIV+TB+ 
HAART- 
(n=18) 
HIV+TB+ 
HAART+ 
(n=13) 
HIV+TB+ HAART- 
vs 
HIV+TB+ HAART+ 
P-value 
HIV+TST+ 
HAART- 
(n=14) 
HIV+TST+ 
HAART+ 
(n=20) 
HIV+TST+ HAART- 
vs 
HIV+TST+ HAART+ 
P-value 
HIV+TST- 
HAART- 
(n=16) 
HIV+TST- 
HAART+ 
(n=26) 
HIV+TST- HAART- 
vs 
HIV+TST- HAART+ 
P-value 
T cell subset markers         
CD3E 14.1 (13.6-14.2) 14.1 (13.5-14.6) 0.5462 14.1 (13.7-14.4) 13.5 (13.2-14.2) 0.0987 14.2 (13.9-14.4) 14.0 (13.9-14.3) 0.2732 
CD4 11.5 (10.9-12.0) 11.5 (11.0-12.2) 0.7452 11.8 (11.4-12.2) 11.4 (10.8-11.9) 0.1077 11.8 (11.4-12.3) 11.5 (10.7-12.0) 0.0872 
IL7R 12.8 (11.9-13.3) 12.6 (11.9-13.5) 0.9630 13.2 (12.7-13.5) 12.7 (11.8-13.3) 0.2803 13.5 (13.2-13.7) 13.0 (12.6-13.5) 0.0422 
PTPRCv1 11.3 (10.6-11.9) 12.0 (11.3-12.3) 0.0569 11.6 (10.9-12.2) 11.5 (10.8-12.4) 0.7995 12.0 (11.3-12.5) 11.4 (11.1-11.8) 0.0543 
PTPRCv2 12.6 (11.9-13.0) 12.8 (12.6-12.9) 0.5459 13.0 (12.7-13.2) 12.6 (12.5-12.9) 0.1077 12.5 (12.0-13.0) 12.8 (12.6-13.1) 0.2189 
Th1/2/9/17 associated genes/Treg associated genes        
IL1B 9.6 (9.2-10.5) 10.0 (9.6-10.5) 0.5459 10.3 (9.8-10.9) 10.2 (9.9-10.4) 0.8989 10.0 (9.8-10.3) 10.2 (9.6-10.7) 0.7484 
IL15 7.6 (7.6-7.7) 7.6 (7.6-7.9) 0.4647 7.6 (7.6-8.1) 7.6 (7.6-7.6) 0.0972 7.6 (7.6-7.6) 7.6 (7.6-7.6) 0.3844 
TBX21 7.6 (7.6-7.7) 7.7 (7.6-8.1) 0.1402 7.6 (7.6-8.0) 7.6 (7.6-7.6) 0.4035 7.6 (7.6-8.2) 7.6 (7.6-7.8) 0.9515 
IL4δ2 9.7 (9.1-10.1) 8.9 (7.6-10.1) 0.3518 9.2 (7.8-10.0) 8.4 (7.6-9.9) 0.3698 9.1 (7.6-9.6) 9.3 (9.1-10.0) 0.1122 
IL9 9.8 (9.2-10.2) 10.0 (9.3-10.2) 1.0000 9.9 (9.6-10.1) 9.4 (8.8-9.8) 0.0826 9.5 (8.8-9.8) 9.7 (9.4-9.8) 0.4073 
IL22RA1 7.6 (7.6-8.0) 7.6 (7.6-7.9) 0.9784 7.7 (7.6-7.8) 7.7 (7.6-8.1) 0.5659 7.6 (7.6-7.8) 7.6 (7.6-7.8) 0.4293 
TGFB1 14.4 (14.1-14.7) 14.7 (14.5-14.9) 0.0326 14.6 (14.4-14.7) 14.6 (14.5-14.7) 0.8324 14.7 (14.5-14.8) 14.6 (14.4-14.8) 0.5930 
Cytotoxicity genes         
GNLY 15.1 (14.2-15.7) 15.3 (14.7-15.5) 0.7805 13.6 (10.1-14.3) 14.8 (13.7-15.0) 0.0132 14.9 (14.6-15.7) 15.1 (14.5-15.3) 0.7283 
GZMB 13.1 (11.9-13.8) 13.7 (13.3-14.0) 0.0776 12.8 (12.4-13.4) 12.6 (12.2-13.1) 0.4717 12.8 (12.5-13.5) 13.1 (12.7-13.6) 0.5212 
Apoptosis/survival         
FLCN1 7.6 (7.6-7.6) 7.6 (7.6-7.9) 0.2444 7.6 (7.6-8.2) 7.6 (7.6-7.9) 0.9049 7.6 (7.6-7.8) 7.6 (7.6-7.7) 0.6273 
TNFRSF1A 13.5 (13.3-13.8) 13.5 (13.4-13.8) 0.9260 13.5 (13.2-13.8) 13.5 (13.4-13.7) 0.8324 13.3 (13.1-13.7) 13.7 (13.2-13.9) 0.5481 
Myeloid associated genes         
CCL5 14.5 (13.6-15.0) 15.2 (14.7-15.5) 0.0511 14.9 (14.3-15.2) 14.8 (14.1-15.2) 0.8989 14.8 (14.6-15.2) 15.0 (14.6-15.3) 0.3635 
FPR1 13.8 (13.6-14.0) 13.8 (12.7-14.3) 1.0000 13.4 (13.0-14.4) 13.7 (13.1-13.9) 0.7995 13.8 (13.0-14.1) 13.6 (13.1-14.0) 0.6885 
Chemokines         
CCL19 9.5 (9.3-9.8) 9.6 (9.4-10.0) 0.2185 9.5 (9.3-9.9) 9.5 (9.3-9.7) 0.5534 9.7 (9.5-9.9) 9.5 (9.3-9.7) 0.0325 
Pattern recognition receptors        
CLEC7A 12.6 (11.9-13.0) 12.2 (12.0-12.5) 0.1499 12.6 (12.3-13.1) 12.3 (12.1-12.6) 0.0987 12.4 (12.1-12.6) 12.1 (11.9-12.7) 0.2850 
TLR1 11.1 (9.6-11.5) 11.1 (10.8-11.2) 0.8526 11.2 (10.7-11.8) 10.9 (10.7-11.0) 0.3096 10.7 (10.2-11.1) 10.7 (10.4-11.4) 0.4074 
TLR2 9.0 (8.2-9.7) 9.1 (8.6-9.6) 0.9629 9.0 (8.1-9.7) 9.3 (9.0-9.8) 0.3302 9.2 (8.7-9.4) 9.2 (8.7-9.7) 0.4150 
TLR3 9.8 (8.9-10.6) 9.7 (9.6-10.1) 0.9260 10.1 (9.2-10.8) 10.1 (9.8-10.8) 0.8324 10.2 (9.8-10.6) 10.3 (9.9-10.6) 0.8726 
TLR4 9.9 (8.8-10.3) 10.1 (9.5-10.3) 0.4574 10.0 (9.8-10.2) 10.1 (9.6-10.4) 0.5254 9.6 (9.3-10.1) 10.0 (9.3-10.2) 0.6689 
TLR6 9.3 (8.2-9.6) 9.4 (9.2-9.7) 0.5303 9.4 (9.1-10.0) 9.7 (9.4-10.0) 0.3096 9.1 (8.7-9.5) 9.6 (9.2-9.9) 0.0480 
TLR8 10.7 (7.6-11.5) 10.1 (7.6-11.2) 0.5711 9.9 (8.5-11.0) 10.5 (9.4-11.1) 0.3738 10.5 (9.0-11.3) 9.9 (8.8-10.9) 0.3425 
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Inflammasome components         
NLRC4 9.1 (8.9-9.3) 9.0 (8.9-9.2) 0.4297 9.3 (9.2-9.6) 9.4 (9.1-9.6) 0.8989 9.3 (9.2-9.4) 9.3 (9.1-9.5) 0.9361 
NLRP12 8.0 (7.6-8.7) 8.0 (7.7-8.7) 0.5125 7.9 (7.6-8.3) 8.4 (7.7-8.6) 0.2152 7.8 (7.6-8.1) 7.8 (7.6-8.4) 0.4592 
IFN signalling genes        
FCGR1A 10.8 (10.3-11.2) 10.9 (10.5-11.6) 0.5462 11.1 (10.4-11.8) 10.6 (10.3-10.2) 0.1624 10.7 (10.5-11.3) 10.6 (9.7-11.4) 0.5212 
Inflammation         
MMP9 9.6 (8.7-11.1) 9.5 (9.0-10.5) 0.8527 8.5 (8.3-9.0) 9.4 (8.9-10.1) 0.0178 9.4 (8.8-10.0) 8.8 (8.4-9.3) 0.0215 
SPP1 7.7 (7.6-8.2) 7.7 (7.6-9.1) 0.5516 7.8 (7.6-7.9) 8.3 (7.6-8.5) 0.0606 8.0 (7.6-8.6) 7.6 (7.6-8.2) 0.1816 
TIMP2 14.3 (14.0-14.6) 14.1 (13.8-14.4) 0.2458 14.1 (13.9-14.7) 14.2 (14.0-14.3) 0.8324 14.2 (13.9-14.6) 14.1 (13.8-14.3) 0.3227 
Other          
RAB24 11.7 (11.5-12.0) 11.8 (11.3-12.0) 0.7103 11.7 (11.5-12.1) 11.5 (11.3-11.8) 0.2530 11.4 (11.2-11.7) 11.3 (11.0-11.6) 0.3496 
LTF 9.5 (8.5-10.1) 9.2 (8.1-9.6) 0.3764 8.7 (8.0-9.5) 8.5 (7.9-9.7) 0.9662 9.0 (8.2-9.7) 8.6 (8.1-9.2) 0.2612 
ZNF331 8.2 (7.7-8.8) 8.7 (7.9-9.6) 0.1902 8.9 (8.2-9.4) 9.3 (8.5-9.7) 0.3302 8.7 (8.2-9.3) 9.0 (8.6-9.6) 0.1995 
BLR1 9.8 (8.8-10.5) 10.8 (9.9-11.5) 0.0121 10.1 (9.6-11.0) 10.5 (10.0-11.1) 0.4212 10.5 (10.1-11.0) 10.6 (9.8-10.9) 0.7688 
 
Median (inter quartile range) gene expression values (peak areas normalized for GAPDH and log2-transformed) are shown at 6 months following treatment initiation. Significant differences 
between ATT and ATT plus HAART treated HIV+TB+ patients, HAART treated and untreated HIV+TST+ subjects, and HAART treated and untreated HIV+TST- individuals were determined using 
Wilcoxon Mann-Whitney test. In pink: genes are indicated that were more highly expressed in the HAART treated group compared to the HAART untreated group. In blue: genes are indicated that 
had lower expression in the HAART treated group compared to the HAART untreated group. Genes listed in this table were differentially expressed between any of the study groups before 
stratification by HAART (in)eligibility (Table 1). 
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Table 3A. Kinetic profiling of the ATT treatment response at the transcriptomic level in HAART treated HIV+TB+ patients compared to HAART eligible HIV+TB+, 
HAART treated HIV+TST+ and HAART treated HIV+TST- subjects. 
 
Gene 
Symbol 
HIV+TB+ 
(M0) 
(n=13) 
HIV+TB+ 
(M6) 
(n=13) 
HIV+TST+ 
(M6) 
(n=20) 
HIV+TST- 
(M6) 
(n=26) 
HIV+TB+ (M6) vs 
HIV+TB+ (M0) 
HIV+TB+ (M6) vs 
HIV+TST+ (M6) 
HIV+TB+ (M6) vs 
HIV+TST- (M6) 
T cell subset markers       
CD3E 13.0 (12.3-13.7) 14.  (13.5-14.6) 13.5 (13.2-14.2) 14.0 (13.9-14.3) 0.0022 0.1384 0.6732 
CD4 11.7 (10.7-12.2) 11.5 (11.0-12.2) 11.4 (10.8-11.9) 11.5 (10.7-12.0) 0.4328 
 
0.4717 0.6732 
IL7R 11.6 (10.8-12.3) 12.6 (11.9-13.5) 12.7 (11.8-13.3) 13.0 (12.6-13.5) 0.0150 1.0000 0.3636 
PTPRCv1 10.9 (10.5-11.4) 12.0 (11.3-12.3) 11.5 (10.8-12.4) 11.4 (11.1-11.8) 0.0150 0.7670 0.1194 
PTPRCv2 13.3 (12.9-13.4) 12.8 (12.6-12.9) 12.6 (12.5-12.9) 12.8 (12.6-13.1) 0.0060 0.4717 0.7456 
Th1/2/9/17 associated genes/Treg associated genes      
IL1B 11.3 (11.0-11.5) 10.0 (9.6-10.5) 10.2 (9.9-10.4) 10.2 (9.6-10.7) 0.0022 0.2899 0.5376 
IL15 7.9 (7.6-8.3) 7.6 (7.6-7.9) 7.6 (7.6-7.6) 7.6 (7.6-7.6) 0.0681 0.1087 0.1489 
TBX21 7.6 (7.6-7.6) 7.7 (7.6-8.1) 7.6 (7.6-7.6) 7.6 (7.6-7.8) 0.2038 0.0863 0.2795 
IL4δ2 7.6 (7.6-7.6) 8.9 (7.6-10.1) 8.4 (7.6-9.9) 9.3 (9.1-10.0) 0.1127 0.4528 0.5356 
IL9 10.0 (9.7-10.2) 10.0 (9.3-10.2) 9.4 (8.8-9.8) 9.7 (9.4-9.8) 0.2721 0.0687 0.1943 
IL22RA1 7.6 (7.6-7.9) 7.6 (7.6-7.9) 7.7 (7.6-8.1) 7.6 (7.6-7.8) 0.7122 0.2580 0.6121 
TGFB1 14.5 (14.4-14.7) 14.7 (14.5-14.9) 14.6 (14.5-14.7) 14.6 (14.4-14.8) 0.2393 0.2899 0.2428 
Cytotoxicity genes       
GNLY 13.9 (13.5-14.3) 15.3 (14.7-15.5) 14.8 (13.7-15.0) 15.1 (14.5-15.3) 0.0342 0.0655 0.4173 
GZMB 12.8 (12.6-13.0) 13.7 (13.3-14.0) 12.6 (12.2-13.1) 13.1 (12.7-13.6) 0.0096 0.0035 0.0410 
Apoptosis/survival       
FLCN1 8.2 (7.8-8.5) 7.6 (7.6-7.9) 7.6 (7.6-7.9) 7.6 (7.6-7.7) 0.0544 0.7688 0.7481 
TNFRSF1A 13.4 (13.1-13.7) 13.5 (13.4-13.8) 13.5 (13.4-13.7) 13.7 (13.2-13.9) 0.4802 0.8324 0.9483 
Myeloid associated genes       
CCL5 14.8 (14.6-15.0) 15.2 (14.7-15.5) 14.8 (14.1-15.2) 15.0 (14.6-15.3) 0.0844 0.2196 0.3468 
FPR1 13.9 (13.6-14.4) 13.8 (12.7-14.3) 13.7 (13.1-13.9) 13.6 (13.1-14.0) 0.3465 0.7670 0.4957 
Chemokines       
CCL19 8.3 (7.6-8.9) 9.6 (9.4-10.0) 9.5 (9.3-9.7) 9.5 (9.3-9.7) 0.0076 0.1892 0.3304 
Pattern recognition receptors      
CLEC7A 12.9 (12.6-13.5) 12.2 (12.0-12.5) 12.3 (12.1-12.6) 12.1 (11.9-12.7) 0.0037 0.4982 0.6732 
TLR1 12.0 (11.5-12.3) 11.1 (10.8-11.2) 10.9 (10.7-11.0) 10.7 (10.4-11.4) 0.0029 0.3740 0.4754 
TLR2 9.9 (9.6-10.5) 9.1 (8.6-9.6) 9.3 (9.0-9.8) 9.2 (8.7-9.7) 0.0150 0.3302 0.6851 
TLR3 10.2 (9.8-10.7) 9.7 (9.6-10.1) 10.1 (9.8-10.8) 10.3 (9.9-10.6) 0.1823 0.1894 0.1119 
TLR4 10.6 (10.2-11.0) 10.1 (9.5-10.3) 10.1 (9.6-10.4) 10.0 (9.3-10.2) 0.0186 0.6721 0.6265 
TLR6 10.1 (9.8-10.4) 9.4 (9.2-9.7) 9.7 (9.4-10.0) 9.6 (9.2-9.9) 0.0186 0.0515 0.2700 
TLR8 11.4 (10.0-12.2) 10.1 (7.6-11.2) 10.5 (9.4-11.1) 9.9 (8.8-10.9) 0.0096 0.3506 0.9222 
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Inflammasome components       
NLRC4 9.8 (9.6-10.0) 9.0 (8.9-9.2) 9.4 (9.1-9.6) 9.3 (9.1-9.5) 0.0022 0.0111 0.0297 
NLRP12 8.2 (8.0-8.6) 8.0 (7.7-8.7) 8.4 (7.7-8.6) 7.8 (7.6-8.4) 0.4802 0.9662 0.3468 
IFN signalling genes       
FCGR1A 11.4 (11.0-11.9) 10.9 (10.5-11.6) 10.6 (10.3-10.2) 10.6 (9.7-11.4 0.0281 0.3627 0.3145 
Inflammation       
MMP9 10.2 (9.1-10.5) 9.5 (9.0-10.5) 9.4 (8.9-10.1) 8.8 (8.4-9.3) 0.5303 0.5254 0.0104 
SPP1 7.6 (7.6-7.6) 7.7 (7.6-9.1) 8.3 (7.6-8.5) 7.6 (7.6-8.2) 0.1482 0.6960 0.4162 
TIMP2 14.5 (13.9-15.3) 14.1 (13.8-14.4) 14.2 (14.0-14.3) 14.1 (13.8-14.3) 0.1361 0.7670 0.8457 
 
Other        
RAB24 11.9 (11.5-12.0) 11.8 (11.3-12.0) 11.5 (11.3-11.8) 11.3 (11.0-11.6) 0.1361 0.4212 0.0980 
LTF 8.8 (7.6-9.7) 9.2 (8.1-9.6) 8.5 (7.9-9.7) 8.6 (8.1-9.2) 0.7828 0.7026 
 
0.2761 
ZNF331 7.8 (7.6-8.0) 8.7 (7.9-9.6) 9.3 (8.5-9.7) 9.0 (8.6-9.6) 0.0202 0.3738 
 
0.2842 
BLR1 9.4 (9.1-10.1) 10.8 (9.9-11.5) 10.5 (10.0-11.1) 10.6 (9.8-10.9) 0.0121 0.4717 0.2700 
 
Median (inter quartile range) gene expression values (peak areas normalized for GAPDH and log2-transformed) are shown. Significant differences between HAART eligible HIV+TB+ patients 
at baseline (Month 0) and 6 months following HAART and ATT treatment initiation (Month 6) were determined using Wilcoxon signed-rank test. Significant differences between the 
different HAART treated study groups at the 6 month time point was determined using Wilcoxon Mann-Whitney test. In pink: genes are indicated that were more highly expressed in the 
test group compared to the reference/control group. In blue: genes are indicated that had lower expression in the test group compared to the reference/control group. Genes listed in this 
table were differentially expressed between any of the study groups before stratification by HAART (in)eligibility (Table 1). 
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Table 3B. Kinetic profiling of the ATT treatment response at the transcriptomic level in HAART untreated HIV+TB+ patients compared to HAART ineligible HIV+TB+, HAART 
untreated HIV+TST+ and HAART untreated HIV+TST- subjects. 
Gene 
Symbol 
HIV+TB+ 
(M0) 
(n=18) 
HIV+TB+ 
(M6) 
(n=18) 
HIV+TST+ 
(M6) 
(n=14) 
HIV+TST- 
(M6) 
(n=16) 
HIV+TB+ (M6) vs 
HIV+TB+ (M0) 
HIV+TB+ (M6) vs 
HIV+TST+ (M6) 
HIV+TB+ (M6) vs 
HIV+TST- (M6) 
T cell subset markers       
CD3E 13.0 (12.5-13.4) 14.  (13.6-14.2) 14.  (13.7-14.4) 14.2 (13.9-14.4) 0.0045 0.6425 0.2744 
CD4 11.5 (10.8-12.0) 11.5 (10.9-12.0) 11.8 (11.4-12.2) 11.8 (11.4-12.3) 0.3343 0.2458 0.1223 
IL7R 11.9 (10.9-12.2) 12.8 (11.9-13.3) 13.2 (12.7-13.5) 13.5 (13.2-13.7) 0.0076 0.2856 0.0075 
PTPRCv1 10.1 (9.8-11.5) 11.3 (10.6-11.9) 11.6 (10.9-12.2) 12.0 (11.3-12.5) 0.4265 0.3898 0.0499 
PTPRCv2 13.4 (13.0-13.7) 12.6 (11.9-13.0) 13.0 (12.7-13.2) 12.5 (12.0-13.0) 0.0064 0.1431 0.8801 
Th1/2/9/17 associated genes/Treg associated genes      
IL1B 11.6 (11.2-11.8) 9.6 (9.2-10.5) 10.3 (9.8-10.9) 10.0 (9.8-10.3) 0.0008 
 
0.2011 0.2276 
IL15 7.8 (7.6-8.2) 7.6 (7.6-7.7) 7.6 (7.6-8.1) 7.6 (7.6-7.6) 0.0719 0.2669 0.0915 
TBX21 7.6 (7.6-7.6) 7.6 (7.6-7.7) 7.6 (7.6-8.0) 7.6 (7.6-8.2) 0.2313 0.4012 
 
0.5059 
IL4δ2 10.5 (7.6-12.1) 9.7 (9.1-10.1) 9.2 (7.8-10.0) 9.1 (7.6-9.6) 0.7982 0.4712 0.0582 
IL9 10.3 (9.6-10.5) 9.8 (9.2-10.2) 9.9 (9.6-10.1) 9.5 (8.8-9.8) 0.3627 0.9222 0.0631 
IL22RA1 7.8 (7.6-9.0) 7.6 (7.6-8.0) 7.7 (7.6-7.8) 7.6 (7.6-7.8) 0.1704 0.5540 0.7782 
TGFB1 14.4 (14.2-14.5) 14.4 (14.1-14.7) 14.6 (14.4-14.7) 14.7 (14.5-14.8) 0.7764 0.3293 0.0545 
Cytotoxicity genes       
GNLY 14.0 (12.8-14.3) 15.1 (14.2-15.7) 13.6 (10.1-14.3) 14.9 (14.6-15.7) 0.1398 0.0091 0.6784 
GZMB 12.6 (12.1-13.0) 13.1 (11.9-13.8) 12.8 (12.4-13.4) 12.8 (12.5-13.5) 0.8203 0.7451 0.9399 
Apoptosis/survival       
FLCN1 7.6 (7.6-8.2) 7.6 (7.6-7.6) 7.6 (7.6-8.2) 7.6 (7.6-7.8) 0.0299 
 
0.0767 0.1371 
TNFRSF1A 13.4 (13.2-13.8) 13.5 (13.3-13.8) 13.5 (13.2-13.8) 13.3 (13.1-13.7) 0.1914 0.8527 0.3230 
Myeloid associated genes      
CCL5 14.6 (14.0-14.8) 14.5 (13.6-15.0) 14.9 (14.3-15.2) 14.8 (14.6-15.2) 0.6496 0.3176 0.1870 
FPR1 14.0 (13.2-14.4) 13.8 (13.6-14.0) 13.4 (13.0-14.4) 13.8 (13.0-14.1) 0.9547 0.5157 0.7919 
Chemokines       
CCL19 8.9 (8.4-9.2) 9.5 (9.3-9.8) 9.5 (9.3-9.9) 9.7 (9.5-9.9) 0.0007 0.3777 0.0418 
Pattern recognition receptors      
CLEC7A 13.1 (12.8-13.5) 12.6 (11.9-13.0) 12.6 (12.3-13.1) 12.4 (12.1-12.6) 0.0268 0.5612 0.5717 
TLR1 12.0 (11.6-12.6) 11.1 (9.6-11.5) 11.2 (10.7-11.8) 10.7 (10.2-11.1) 0.0012 
 
0.4431 0.5717 
TLR2 10.1 (9.3-10.6) 9.0 (8.2-9.7) 9.0 (8.1-9.7) 9.2 (8.7-9.4) 0.0090 0.8523 0.9398 
TLR3 10.3 (10.2-10.7) 9.8 (8.9-10.6) 10.1 (9.2-10.8) 10.2 (9.8-10.6) 0.1118 0.4574 0.3459 
TLR4 10.4 (10.2-11.0) 9.9 (8.8-10.3) 10.0 (9.8-10.2) 9.6 (9.3-10.1) 0.0090 
 
0.5929 0.8505 
TLR6 9.9 (9.6-10.2) 9.3 (8.2-9.6) 9.4 (9.1-10.0) 9.1 (8.7-9.5) 0.0008 0.2455 0.9099 
TLR8 11.8 (10.7-12.4) 10.7 (7.6-11.5) 9.9 (8.5-11.0) 10.5 (9.0-11.3) 0.0146 0.7789 0.8649 
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Inflammasome components       
NLRC4 9.9 (9.6-10.2) 9.1 (8.9-9.3) 9.3 (9.2-9.6) 9.3 (9.2-9.4) 0.0064 0.1143 0.0898 
NLRP12 8.5 (8.0-8.7) 8.0 (7.6-8.7) 7.9 (7.6-8.3) 7.8 (7.6-8.1) 0.1704 
 
0.5686 0.2119 
IFN signalling genes       
FCGR1A 11.4 (10.8-11.8) 10.8 (10.3-11.2) 11.1 (10.4-11.8) 10.7 (10.5-11.3) 0.4265 0.2856 0.9399 
Inflammation       
MMP9 10.9 (8.7-11.4) 9.6 (8.7-11.1) 8.5 (8.3-9.0) 9.4 (8.8-10.0) 0.3201 0.0274 0.5465 
SPP1 7.6 (7.6-8.2) 7.7 (7.6-8.2) 7.8 (7.6-7.9) 8.0 (7.6-8.6) 0.7979 0.9815 0.3652 
TIMP2 14.2 (13.7-14.9) 14.3 (14.0-14.6) 14.1 (13.9-14.7) 14.2 (13.9-14.6) 0.6092 0.5775 0.5718 
Other        
RAB24 11.6 (10.8-12.0) 11.7 (11.5-12.0) 11.7 (11.5-12.1) 11.4 (11.2-11.7) 0.0199 1.0000 0.0458 
LTF 9.1 (8.4-10.7) 9.5 (8.5-10.1) 8.7 (8.0-9.5) 9.0 (8.2-9.7) 0.6092 0.1250 0.2740 
ZNF331 7.6 (7.6-9.1) 8.2 (7.7-8.8) 8.9 (8.2-9.4) 8.7 (8.2-9.3) 0.5887 0.0850 0.0541 
BLR1 9.6 (9.3-9.9) 9.8 (8.8-10.5) 10.1 (9.6-11.0) 10.5 (10.1-11.0) 0.5321 0.2649 0.0215 
 
Median (inter quartile range) gene expression values (peak areas normalized for GAPDH and log2-transformed) are shown. Significant differences between HAART ineligible HIV+TB+ 
patients at baseline (Month 0) and 6 months following ATT treatment initiation (Month 6) were determined using Wilcoxon signed-rank test. Significant differences between the 
different HAART untreated study groups at the 6 month time point was determined using Wilcoxon Mann-Whitney test. In pink: genes are indicated that were more highly expressed in 
the test group compared to the reference/control group. In blue: genes are indicated that were lower expressed in the test group compared to the reference/control group. Genes listed 
in this table were differentially expressed between any of the study groups before stratification by HAART (in)eligibility (Table 1). 
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Figure 1. 
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Figure 2. 
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